A Phase 3 interventional study of azelastine hydrochloride and fluticasone propionate and Dymista vehicle in Seasonal Allergic Rhinitis, sponsored by Meda Pharmaceuticals. Completed at 31 sites in United States. Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2015-06-29.
Sponsored by Meda Pharmaceuticals (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing azelastine in Rhinitis, Allergic, Seasonal — none open to participants now, none under way, none of them phase 3. azelastine · Rhinitis, Allergic, Seasonal.
Among the 16 studies testing azelastine in Rhinitis, Allergic, Seasonal, this one is the 9th largest by enrollment, is the only one that started in 2013, is one of 9 in phase 3, and was the 10th registered.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
Browse Rhinitis, Allergic, Seasonal studies →None of the 16 studies testing azelastine in Rhinitis, Allergic, Seasonal is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →
azelastine: first FDA approval 1996 (ASTELIN). What it is approved for, and how studies give it, is on its page →
Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 4 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 348 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Median enrollment 415 across the 16 interventional studies. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 16 have an industry lead sponsor. The 8 most frequent:
This study is registered under Meda Pharmaceuticals, one of the names counted as Viatris Inc.. Under that name alone:
Meda Pharmaceuticals is the lead sponsor of 19 studies on the registry; none are open to participants now.
15 studies in Rhinitis, Allergic, Seasonal by Viatris Inc.: none open now, none under way, none of them phase 3. Of 15 finished, 10 (67%) have results posted.
Among the 15 studies in Rhinitis, Allergic, Seasonal by Viatris Inc., this one is the 12th largest by enrollment, is one of 2 that started in 2013, is one of 11 in phase 3, and was the 10th registered.
Viatris Inc.’s Rhinitis, Allergic, Seasonal studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing azelastine in Rhinitis, Allergic, Seasonal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 15 in Rhinitis, Allergic, Seasonal:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if Dymista nasal spray is better and safer than placebo in treating children ages 4 to \<12 years old who have seasonal allergic rhinitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At Visit 2:
At Visit 2, to be eligible for entry into the double-blind treatment period, subjects must have the total of the seven lead-in symptom assessments during the past 3 days of the lead-in period including the Day of Randomization (Visit 2, Day 1):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
(azelastine hydrochloride and fluticasone propionate) Nasal Spray, 137mcg/50mcg: Mode of Administration: Topical/intranasal spray Dose: 548 mcg azelastine hydrochloride / 200 mcg fluticasone propionate, total daily dose Regimen: 1 spray per nostril twice daily
Drug: azelastine hydrochloride and fluticasone propionate
Dose: vehicle only Regimen: 1 spray per nostril twice daily
Drug: Dymista vehicle
Drug pages: Azelastine · Fluticasone
Also known as: Dymista
Also known as: placebo
Primary Efficacy
change from baseline in AM+PM rTNSS (reflective total nasal symptoms score): ITT( intent to treat population)change from baseline in 12-hour reflective total nasal symptom score (rTNSS) consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary for the entire 14 day study period.The measurement scale is 0 to 24 so that the higher the number the worse the symptom.A reduction in symptom severity score is indicated by a negative value.A greater negative value suggests improvement.
Time frame: 15 days of treatment
Safety
* Subject-reported adverse experiences (incidence, type, and severity of adverse events) * Nasal Examinations * Vital signs assessments
Time frame: entire length of study (day 1 to day 22)
Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ)
Change from baseline to Visit 4 in the ITT ( intent to treat) Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) in subjects equal to or greater than 6 years old and less than12 years old compared to placebo.Scored on a 0 to 7 scale with 0 being not troubled at all and 7 being extremely troublesome. The higher the difference the better the result.
Time frame: day 1 to day 15 of treatment
| Milestone | Dymista | Dymista Vehicle |
|---|---|---|
| Started | 173 | 175 |
| Completed | 171 | 173 |
| Not completed | 2 | 2 |
change from baseline in AM+PM rTNSS (reflective total nasal symptoms score): ITT( intent to treat population)change from baseline in 12-hour reflective total nasal symptom score (rTNSS) consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary for the entire 14 day study period.The measurement scale is 0 to 24 so that the higher the number the worse the symptom.A reduction in symptom severity score is indicated by a negative value.A greater negative value suggests improvement.
| units on a scale | Dymista | Dymista Vehicle |
|---|---|---|
| Primary Efficacy | -3.83 ± 5.154 | -2.77 ± 4.731 |
* Subject-reported adverse experiences (incidence, type, and severity of adverse events) * Nasal Examinations * Vital signs assessments
| occurance | Dymista | Dymista Vehicle |
|---|---|---|
| Safety | 28 | 23 |
Change from baseline to Visit 4 in the ITT ( intent to treat) Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) in subjects equal to or greater than 6 years old and less than12 years old compared to placebo.Scored on a 0 to 7 scale with 0 being not troubled at all and 7 being extremely troublesome. The higher the difference the better the result.
| units on a scale | Dymista | Dymista Vehicle |
|---|---|---|
| Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) | -.91 ± 1.22 | -.66 ± 1.22 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dymista | — | 0/173 (0%) | 13/173 (7.5%) |
| Dymista Vehicle | — | 0/175 (0%) | 6/175 (3.4%) |
| Event | Dymista | Dymista Vehicle |
|---|---|---|
| dysgusiaNervous system disorders | 7/173 | 0/175 |
| epistaxisRespiratory, thoracic and mediastinal disorders | 6/173 | 6/175 |
| Age, Categorical(Participants) | Dymista | Dymista Vehicle | Total |
|---|---|---|---|
| <=18 years | 173 | 175 | 348 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Dymista | Dymista Vehicle | Total |
|---|---|---|---|
| Mean | 8.5 ± 2.11 | 8.4 ± 2.06 | 8.4 ± 2.08 |
| Sex: Female, Male(Participants) | Dymista | Dymista Vehicle | Total |
|---|---|---|---|
| Female | 77 | 85 | 162 |
| Male | 96 | 90 | 186 |
| Region of Enrollment(participants) | Dymista | Dymista Vehicle | Total |
|---|---|---|---|
| United States | 173 | 175 | 348 |
The record gives a start of Jul 2013 and a primary completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Azelastine · Fluticasone
Rhinitis, Allergic, Seasonal →